111 related articles for article (PubMed ID: 23603101)
41. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy.
Söderpalm AC; Magnusson P; Ahlander AC; Karlsson J; Kroksmark AK; Tulinius M; Swolin-Eide D
Neuromuscul Disord; 2007 Dec; 17(11-12):919-28. PubMed ID: 17627820
[TBL] [Abstract][Full Text] [Related]
42. Elevated satellite cell number in Duchenne muscular dystrophy.
Kottlors M; Kirschner J
Cell Tissue Res; 2010 Jun; 340(3):541-8. PubMed ID: 20467789
[TBL] [Abstract][Full Text] [Related]
43. Urinary prostaglandin D
Shoji H; Ikeda N; Kitamura T; Suganuma H; Ohba M; Okuno T; Yokomizo T; Shimizu T
Acta Paediatr; 2018 Jan; 107(1):95-100. PubMed ID: 28898456
[TBL] [Abstract][Full Text] [Related]
44. Genetic polymorphism in muscle biopsies of Duchenne and Becker muscular dystrophy patients.
Anand A; Prabhakar S; Kaul D
Neurol India; 1999 Sep; 47(3):218-23. PubMed ID: 10514583
[TBL] [Abstract][Full Text] [Related]
45. Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study.
Mavrogeni S; Papavasiliou A; Douskou M; Kolovou G; Papadopoulou E; Cokkinos DV
Eur J Paediatr Neurol; 2009 Jan; 13(1):34-40. PubMed ID: 18406648
[TBL] [Abstract][Full Text] [Related]
46. [Relationship between gene mutations and intelligence in children with Duchenne muscular dystrophy].
Wang LB; Ma HW; Wang L; Tian XB; Hu M; Ren S; Tan YH
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Oct; 13(10):804-7. PubMed ID: 22000435
[TBL] [Abstract][Full Text] [Related]
47. Valley sign in duchenne muscular dystrophy: importance in patients with inconspicuous calves.
Pradhan S
Neurol India; 2002 Jun; 50(2):184-6. PubMed ID: 12134184
[TBL] [Abstract][Full Text] [Related]
48. [Study of the gene deletions and the immunofluorescence of muscle in patients with DMD/BMD].
Dong YH; Lu PY; Wei C; Wang HB; Zhao BH
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2005 Nov; 21(4):453-6. PubMed ID: 21180173
[TBL] [Abstract][Full Text] [Related]
49. Repolarization abnormalities in Duchenne-type muscular dystrophy.
Yilmazer MM; Omeroğlu RE; Bornaun H; Oner N; Nişli K; Ertuğrul T
Turk Kardiyol Dern Ars; 2009 Dec; 37(8):538-42. PubMed ID: 20200454
[TBL] [Abstract][Full Text] [Related]
50. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
51. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
[TBL] [Abstract][Full Text] [Related]
52. Health-related quality of life in children and adolescents with Duchenne muscular dystrophy.
Uzark K; King E; Cripe L; Spicer R; Sage J; Kinnett K; Wong B; Pratt J; Varni JW
Pediatrics; 2012 Dec; 130(6):e1559-66. PubMed ID: 23129083
[TBL] [Abstract][Full Text] [Related]
53. [Genotype-phenotype discordance in a Duchenne muscular dystrophy patient due to a novel mutation: insights into the shock absorber function of dystrophin].
López-Hernández LB; van Heusden D; Soriano-Ursúa MA; Figuera-Villanueva L; Vázquez-Cárdenas NA; Canto P; Gómez-Díaz B; Coral-Vázquez RM
Rev Neurol; 2011 Jun; 52(12):720-4. PubMed ID: 21594857
[TBL] [Abstract][Full Text] [Related]
54. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis.
Cho C; Nguyen A; Bryant KJ; O'Neill SG; McNeil HP
Immun Inflamm Dis; 2016 Mar; 4(1):64-9. PubMed ID: 27042302
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of urinary prostaglandin E2 metabolite as a biomarker in infants with fever due to viral infection.
Idborg H; Pawelzik SC; Perez-Manso M; Björk L; Hamrin J; Herlenius E; Jakobsson PJ
Prostaglandins Leukot Essent Fatty Acids; 2014 Dec; 91(6):269-75. PubMed ID: 25305792
[TBL] [Abstract][Full Text] [Related]
56. Urinary prostaglandin D
Pawelzik SC; Avignon A; Idborg H; Boegner C; Stanke-Labesque F; Jakobsson PJ; Sultan A; Bäck M
Prostaglandins Other Lipid Mediat; 2019 Dec; 145():106361. PubMed ID: 31419481
[TBL] [Abstract][Full Text] [Related]
57. Orofacial dysfunction in Duchenne muscular dystrophy.
Botteron S; Verdebout CM; Jeannet PY; Kiliaridis S
Arch Oral Biol; 2009 Jan; 54(1):26-31. PubMed ID: 18805518
[TBL] [Abstract][Full Text] [Related]
58. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.
Hathout Y; Brody E; Clemens PR; Cripe L; DeLisle RK; Furlong P; Gordish-Dressman H; Hache L; Henricson E; Hoffman EP; Kobayashi YM; Lorts A; Mah JK; McDonald C; Mehler B; Nelson S; Nikrad M; Singer B; Steele F; Sterling D; Sweeney HL; Williams S; Gold L
Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7153-8. PubMed ID: 26039989
[TBL] [Abstract][Full Text] [Related]
59. Protein and energy metabolism in patients with progressive muscular dystrophy.
Okada K; Manabe S; Sakamoto S; Ohnaka M; Niiyama Y
J Nutr Sci Vitaminol (Tokyo); 1992 Apr; 38(2):141-54. PubMed ID: 1506920
[TBL] [Abstract][Full Text] [Related]
60. Decreased gray matter concentration and local synchronization of spontaneous activity in the motor cortex in Duchenne muscular dystrophy.
Lv SY; Zou QH; Cui JL; Zhao N; Hu J; Long XY; Sun YC; He J; Zhu CZ; He Y; Zang YF
AJNR Am J Neuroradiol; 2011 Dec; 32(11):2196-200. PubMed ID: 21960496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
